Navigation Links
AIT Bioscience Taps Ligand Binding Assay Expert Dr. Ron Bowsher as Senior Research Advisor
Date:9/11/2012

INDIANAPOLIS, Sept. 12, 2012 /PRNewswire/ -- AIT Bioscience is pleased to announce that Dr. Ron Bowsher, an industry expert in bioanalysis of ligand binding assays, has partnered with the company as a senior research advisor bringing with him an impressive background in biotherapeutic drug research in both traditional pharmaceutical and the CRO industries.

"I am excited about my advisory role at AIT Bioscience, because I believe this organization is both highly innovative and customer-focused," said Dr. Bowsher, who has a long and illustrious history in biotherapeutic research and is a pioneer in regulated bioanalysis of macromolecules.

"The AIT Bioscience team is dedicated to providing both innovative and quality services as demonstrated by their cutting-edge use of electronic lab notebooks. I'm looking forward to helping them grow and expand their services for bioanalysis of large molecules, in order to help clients achieve expedited, quality data," he says.  In his role as senior research advisor of ligand binding assays, Dr. Bowsher will advise on technical, regulatory, and business development matters related to ligand binding methods.

"Dr. Bowsher is a pioneer in our industry and we are honored to have him as an advisor to our management team. His demonstrated leadership in ligand binding assays opens our services to a broader pipeline of molecules, allowing more clinical and non-clinical studies to benefit from our fully integrated electronic laboratory documentation system," said AIT Bioscience president Dr. Ron Shoup.

Dr. Bowsher brings more than 35 years experience in the pharmaceutical/biotech and contract research organization industries. He received a bachelor's degree in chemistry from Indiana University and holds a master's degree and doctorate in biochemistry from the Indiana University School of Medicine. He is an adjunct assistant professor of biochemistry and molecular biology at the IU School of Medicine. In addition to his new advisory role at AIT Bioscience, Dr. Bowsher maintains his robust consulting and laboratory businesses at B2S Consulting® (Indianapolis, IN), and B2S Labs (Shelbyville, IN), respectively.  Since 1980 he has published more than 100 research papers and monographs and 105 abstracts. He holds three patents. He is an AAPS Fellow and was awarded an AAPS Presidential Citation for his work on establishing an educational program for ligand binding assays.  In 2012, Dr. Bowsher received the Distinguished Alumnus Award, School of Science, Indiana University-Purdue University (IUPUI), Indianapolis IN.

About AIT Bioscience:

AIT Bioscience, LLC, headquartered in Indianapolis, Ind., is a bioanalytical contract research organization supporting pre-clinical and phase I-III clinical trials. AIT Bioscience provides robust analytical methods, automated sample logistics, with a systems-wide Quality by Design (QbD) operation that support programs through to the investigational new drug and new drug applications. AIT Bioscience has created a new standard for quantitative bioanalytical analysis and drug development in support of small biotech and large pharmaceutical companies. Learn more about AIT Bioscience at www.AITBioscience.com.


'/>"/>
SOURCE AIT Bioscience
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
2. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
3. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
4. Neurocrine Biosciences Reports First Quarter 2012 Results
5. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
6. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
7. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
8. HUYA Bioscience International Engages In Partnership With Zhuhai Sanzao Science and Technology Industrial Park
9. Tethys Bioscience and Lose it! Announce a Strategic Partnership to Support Diabetes Prevention
10. 3-V Biosciences To Present at the Seventh Annual JMP Securities Healthcare Conference
11. Sofie Biosciences receives $1M Phase II SBIR grant from the DOE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... , Feb. 4, 2016 Wegener ... Global Markets Direct,s, ,Wegener Polyangiitis - Pipeline ... Wegener Polyangiitis,s therapeutic pipeline. This report provides ... Polyangiitis, complete with comparative analysis at various stages, ... (MoA), route of administration (RoA) and molecule type, ...
(Date:2/4/2016)... 4, 2016 Frontier Pharma: Chronic Obstructive ... Innovation Chronic Obstructive Pulmonary Disease ... inflammation of the airways and lungs. Persistent breathing ... the disease one of the leading causes of ... the world. COPD is linked to cumulative exposure ...
(Date:2/4/2016)... In response to the opioid abuse epidemic, today ... Medical Products and Tobacco, along with other FDA leaders, called ... to opioid medications. The plan will focus on policies aimed ... access to effective relief. --> ... the risk-benefit paradigm for opioids and ensure that the agency ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... US Sports Camps , official ... NH to direct high-performance kids yoga training. ChildLight Yoga Studio is centrally situated in ... from Boston. , ChildLight Yoga Studio founder Lisa Flynn expresses her excitement, “We are ...
(Date:2/5/2016)... ... ... Give To Cure today announced that it is working with ... Cure’s campaign that is crowdfunding clinical trials to help find cures faster for Alzheimer’s ... smart device. In 2015 alone, Venmo processed $7.5 billion in transactions among users. , ...
(Date:2/5/2016)... ... ... Dr. Justin Scott and Dr. Lydia Muccioli of Pure Dental Health ... need. The event is scheduled to take place on February 27, 2016 from 9am ... care to community members in need. Each patient will be given the opportunity to ...
(Date:2/5/2016)... ... February 05, 2016 , ... In sleep, when the ... a dream. A hallmark feature of patients with eating disorders is significant self-criticism, and ... disorder behaviors and obsessions are regarded as maladaptive means for coping with this unease, ...
(Date:2/5/2016)... ... February 05, 2016 , ... Calls Blacklist has just been updated by ... design and the developer has fixed known bugs within the app. Calls Blacklist allows ... phone while not consuming any of their device’s battery power or memory. It provides ...
Breaking Medicine News(10 mins):